Advertisement
Advertisement
U.S. markets close in 5 hours 21 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Genmab A/S (0MGB.IL)

IOB - IOB Delayed Price. Currency in DKK
2,571.00+1.00 (+0.04%)
As of 03:06PM BST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2,570.00
Open2,602.00
Bid2,524.00 x 0
Ask2,629.00 x 0
Day's Range2,571.00 - 2,607.00
52 Week Range1,864.00 - 3,325.00
Volume24,434
Avg. Volume20,532
Market Cap168.914B
Beta (5Y Monthly)0.71
PE Ratio (TTM)30.22
EPS (TTM)85.08
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 0MGB.IL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

      Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria a

    • GlobeNewswire

      Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

      Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 90,054 restricted stock units to members of management and employees of the Company and the Company’s subsidiaries and 16,276 warrants to the employees of the Compa

    • GlobeNewswire

      Passing of Genmab A/S’ Annual General Meeting

      Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2023, the Annual Report for 2022 was approvedDischarge was given to the Board of Directors and the Executive Management and the year’s profit was carried forwardThe 2022 Compensation Report was approvedSix members of the Board of Directors were re-electedPricewaterhouseCoopers was re-elected as auditor of the CompanyThe proposals from the Board of Directors on the Board of Directors' remuneration for 2023, the propos

    Advertisement
    Advertisement